Trade BridgeBio Pharma, Inc. - BBIO CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.15 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023346% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001124% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 35.88 |
| Open | 35.3 |
| 1-Year Change | 41.48% |
| Day's Range | 35.2 - 36.25 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 24, 2025 | 35.88 | 0.98 | 2.81% | 34.90 | 35.92 | 34.55 |
| Apr 23, 2025 | 35.16 | 0.21 | 0.60% | 34.95 | 36.03 | 34.79 |
| Apr 22, 2025 | 34.10 | 0.30 | 0.89% | 33.80 | 34.39 | 33.47 |
| Apr 21, 2025 | 33.46 | 0.01 | 0.03% | 33.45 | 34.23 | 33.11 |
| Apr 17, 2025 | 33.79 | 0.51 | 1.53% | 33.28 | 34.23 | 33.28 |
| Apr 16, 2025 | 33.80 | -0.16 | -0.47% | 33.96 | 34.29 | 33.04 |
| Apr 15, 2025 | 34.15 | -0.33 | -0.96% | 34.48 | 35.03 | 33.77 |
| Apr 14, 2025 | 34.77 | 0.48 | 1.40% | 34.29 | 34.96 | 33.53 |
| Apr 11, 2025 | 33.85 | 1.90 | 5.95% | 31.95 | 34.01 | 31.46 |
| Apr 10, 2025 | 32.23 | 0.68 | 2.16% | 31.55 | 32.78 | 29.96 |
| Apr 9, 2025 | 32.79 | 3.41 | 11.61% | 29.38 | 33.09 | 28.25 |
| Apr 8, 2025 | 30.08 | -1.74 | -5.47% | 31.82 | 32.45 | 29.38 |
| Apr 7, 2025 | 30.61 | 1.44 | 4.94% | 29.17 | 32.18 | 28.76 |
| Apr 4, 2025 | 31.30 | -1.75 | -5.30% | 33.05 | 33.77 | 30.79 |
| Apr 3, 2025 | 34.02 | 0.82 | 2.47% | 33.20 | 34.79 | 33.07 |
| Apr 2, 2025 | 34.54 | 1.95 | 5.98% | 32.59 | 34.67 | 32.54 |
| Apr 1, 2025 | 32.96 | -0.74 | -2.20% | 33.70 | 34.40 | 32.77 |
| Mar 31, 2025 | 34.53 | -0.55 | -1.57% | 35.08 | 35.20 | 33.69 |
| Mar 28, 2025 | 35.03 | -0.87 | -2.42% | 35.90 | 36.05 | 34.90 |
| Mar 27, 2025 | 36.33 | 0.18 | 0.50% | 36.15 | 36.96 | 35.96 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
BridgeBio Pharma, Inc. Company profile
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include BBP-265, a small molecule stabilizer of transthyretin, or TTR, that is in an ongoing Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor which is an ongoing Phase 2 clinical trial for the treatment of achondroplasia in pediatric patients; an AAV5 gene transfer product candidate for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD; and Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, an ongoing phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1. The company also engages in developing products for Mendelian, genetic dermatology, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; The Regents of the University of California; Leidos Biomedical Research, Inc.; the University of California, San Diego; Johns Hopkins University and University of Florida; University of Colorado Anschutz Medical Campus; Salk Institute for Biological Studies; Maze Therapeutics; UC San Francisco; the Canadian Glycomics Network (GlycoNet); the University of California; Columbia University; Mount Sinai; and Helsinn Group, as well as a clinical collaboration with Bristol Myers Squibb to evaluate the combination of BBP-398. It also has a research collaboration and option agreement with Unnatural Products Inc. to target rare diseases with potential oncology applications. The company was founded in 2015 and is headquartered in Palo Alto, California.| Industry: | Biopharmaceuticals |
3160 Porter Dr.
Suite 250
PALO ALTO
CALIFORNIA 94304
US
News
ECB interest-rate forecasts – Projections for the next five years
The European Central Bank (ECB) plays a pivotal role in the economic stability of the eurozone, meaning ECB interest-rate forecasts are key to understanding how financial and economic scenarios might evolve.
14:37, 10 April 2025
BlackRock shareholders: Who owns the most BLK stock?
BlackRock is the leading asset manager in the world – but who are its biggest shareholders? Read on to find out.
13:46, 9 April 2025
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
10:28, 9 April 2025
Tesla (TSLA) stock forecast 2025 and beyond: third-party Tesla price target
Where will Tesla’s stock be in five years? Can the EV company keep its crown?
08:19, 9 April 2025
JasmyCoin price predictions 2025-2030: Third-party price target
How might JASMY behave in the future?
16:13, 8 April 2025
Australian interest-rate projections: where will rates be in 5 years?
As one of the most closely watched economic indicators, Australian interest-rate projections offer valuable insight into the future of the country’s economy.
21:37, 7 April 2025
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025People also watch
Still looking for a broker you can trust?
Join the 720,000+ traders worldwide that chose to trade with Capital.com